ArticleEuropean journal of case reports in internal medicine2026
Pancreatic Metastases from Urothelial Cancer.
Article in European journal of case reports in internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Urothelial carcinoma (UC) is a common malignancy that rarely metastasizes to the pancreas. Pancreatic masses in patients with UC present significant diagnostic challenges. Case report: An elderly man with a history of nephroureterectomy for UC of the renal pelvis presented with lower back pain, nausea, and constipation. Imaging revealed local relapse and a solitary pancreatic mass. Endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) confirmed the diagnosis of metastatic UC. The patient was treated with carboplatin and gemcitabine and subsequently with pembrolizumab but experienced rapid progression and succumbed to his disease. Conclusion: Pancreatic metastases from UC are extremely rare. Accurate diagnosis requires histological confirmation, and EUS-FNB provides a minimally invasive and effective method. Management should be individualized, and the role of multidisciplinary team involvement is critical. LEARNING POINTS: In patients with a history of advanced urothelial carcinoma, the possibility of a pancreatic mass being metastatic, though uncommon, should always be considered in the differential diagnosis.Multidisciplinary team involvement is crucial for optimal diagnostic and management decisions.Histological confirmation is mandatory, and endoscopic ultrasound-guided fine needle biopsy is the most accurate and minimally invasive approach for obtaining tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.